BOSTON, Sept. 29, 2016 /PRNewswire-iReach/ -- Frameshift Genomics today announced that it has secured Federal Government support through a small business award (STTR). In collaboration with the laboratory of Professor Gabor Marth at the University of Utah, this funding will be used to further develop their genomics platform, iobio, which enables rapid, user-friendly analysis of large scale genomic data.
Photo - http://photos.prnewswire.com/prnh/20160928/412925LOGO
Frameshift and the Marth lab are opening up the world of genomic analysis to all, by developing a web-based system capable of powerful visually-driven analysis of DNA sequencing data in real-time. These analysis methods represent a paradigm shift in the way genomic data is used since they will enable powerful analysis by users who need to understand their data but do not have specialized computational skills.
"Currently, genomic analysis is performed by bioinformaticians who have a lot of computational and algorithmics expertise," said Dr. Ward, a co-founder of Frameshift. "Clinicians have to rely on the static analysis reports that are provided to them. Using iobio apps, clinicians enter the analysis at the ground floor, bringing their extensive knowledge of disease genetics to bear at the beginning of the analysis, where it is needed".
The coordination of real-time analysis and visualization is a novel feature of the iobio platform. "Combining real-time analysis and custom visualizations enables researchers to ask more questions, and quickly follow up on their hypotheses, curiosities, and insights. It's surprising how many more questions you ask when you get results in seconds as opposed to hours or days. This stronger relationship with the data is needed to get the most insight from these big, complex data sets," stated Dr. Miller, a co-founder.
Frameshift was cofounded by Prof. Gabor Marth, Dr. Alistair Ward and Dr. Chase Miller. Prof. Marth is a highly respected PI, with a long history of developing key algorithmic tools to support bioinformatics analysis, both in inherited disease and cancers. Dr. Ward is an expert in developing and deploying bioinformatic pipelines and interpreting their results to aid discovery of genetic causes of disease. Dr. Miller is a leader in big genomic web applications and has developed multiple, widely-used visualization tools, libraries, and web applications.
The iobio project can be found at iobio.io and visit frameshift.io for more information on the company.The research reported here is supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number R41HG009096. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Media Contact: Chase Miller, Frameshift Genomics, 9042334873, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
For more information:
Last updated on: 30/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.